Implementation Checklists for High Quality RWE Study Execution The establishment of high-quality Real-World Evidence (RWE) is critical for regulatory submissions to the FDA, especially as these evidence types gain traction in informing clinical decisions and regulatory actions. This tutorial will explore the essential checklists and methodologies necessary for executing RWE studies that meet the expectations of the FDA and other international regulatory bodies. Professionals in regulatory affairs, biostatistics, health economics and outcomes research (HEOR), and data standards will find this guide particularly valuable. Understanding the Need for RWE in Regulatory Submissions RWE is derived from data collected outside of traditional…

Bridging RCT and RWE Evidence for Robust Benefit-Risk Assessments The integration of randomized controlled trial (RCT) data and real-world evidence (RWE) is becoming increasingly vital for regulatory submissions and decision-making in the pharmaceutical and medical devices sectors. This tutorial provides a step-by-step guide on how to effectively design RWE studies that meet FDA requirements and bridge this critical gap in evidence generation for benefit-risk assessments. Understanding FDA Regulations and Guidelines for RWE The FDA has recognized the importance of RWE in complementing traditional RCTs. According to the FDA’s framework for incorporating RWE in regulatory submissions, RWE can demonstrate the effectiveness…

Working with KOLs, Regulators, and Statisticians on RWE Methodology Real-World Evidence (RWE) is becoming increasingly pivotal in regulatory decision-making. As regulatory authorities like the US FDA actively encourage the use of RWE in assessing the safety and effectiveness of medical products, understanding how to collaborate with Key Opinion Leaders (KOLs), regulators, and statisticians in developing robust RWE study design methodology is essential. This tutorial will guide you in navigating these collaborations effectively, focusing specifically on FDA submissions, while referencing UK and EU practices where applicable. Understanding Real-World Evidence (RWE) in the Regulatory Landscape The FDA defines RWE as the clinical…

Pre-specifying RWE Protocols and SAPs for Regulatory Transparency In the evolving landscape of pharmaceutical regulation, the significance of Real-World Evidence (RWE) has grown, particularly regarding regulatory submissions to the U.S. Food and Drug Administration (FDA). Developing robust RWE study design methodologies for FDA submissions is essential for ensuring effective regulatory compliance and securing approval. This article serves as a comprehensive guide for regulatory, biostatistics, Health Economics and Outcomes Research (HEOR), RWE, and data standards professionals in the pharmaceutical and medtech industries. Understanding Regulatory Expectations for RWE The FDA has increasingly highlighted the role of RWE in the drug approval process,…

Case Studies of RWE Submissions Leveraging CDISC Compliant RWD Real-World Evidence (RWE) is increasingly becoming an essential component in regulatory submissions within the pharmaceutical and medical technology industries. As organizations strive to align their data with regulatory expectations, understanding the integration of CDISC (Clinical Data Interchange Standards Consortium) frameworks like SDTM (Study Data Tabulation Model) and ADaM (Analysis Data Model) into real-world data (RWD) submissions is critical. This article provides a comprehensive step-by-step tutorial on leveraging CDISC-compliant RWD, focusing on practical case studies, regulatory guidelines, and integration of data standards. Understanding Real-World Evidence and Its Regulatory Relevance RWE is defined…

Building RWE Data Pipelines that Respect CDISC and FDA Data Standards Building RWE Data Pipelines that Respect CDISC and FDA Data Standards Real-World Evidence (RWE) has increasingly become a cornerstone of modern healthcare decision-making, providing insights beyond traditional clinical trial data. With a growing emphasis on data standards such as CDISC (Clinical Data Interchange Standards Consortium), the importance of developing RWE data pipelines compliant with FDA regulations cannot be overstated. In this comprehensive tutorial, we will guide you step by step through building RWE data pipelines that adhere to CDISC and FDA data standards, focusing on the integration of various…

HL7 FHIR as a Bridge Between EHR Data and RWE Analytic Datasets HL7 FHIR as a Bridge Between EHR Data and RWE Analytic Datasets The integration of clinical data into real-world evidence (RWE) analytics is a critical component of driving innovation and regulatory compliance in the pharmaceutical and medtech industries. A prominent framework that helps in achieving this integration is Health Level 7 Fast Healthcare Interoperability Resources (HL7 FHIR). This tutorial will provide a comprehensive step-by-step guide to understanding how HL7 FHIR acts as a bridge between Electronic Health Record (EHR) data and RWE analytic datasets, focusing on critical aspects…

Converting Messy RWD into CDISC SDTM and ADaM Formats for Regulators Real-world data (RWD) has become increasingly significant in determining healthcare outcomes, drug efficacy, and safety. As regulatory bodies like the U.S. Food and Drug Administration (FDA) continue to evolve their initiatives, a standardized approach to data representation becomes essential in ensuring compliance and facilitating regulatory review. One core component of this initiative involves structuring RWD into Clinical Data Interchange Standards Consortium (CDISC) formats, namely the Study Data Tabulation Model (SDTM) and the Analysis Data Model (ADaM). This tutorial serves as a comprehensive guide for professionals in pharma and medtech…

Regulatory Expectations for Traceability from Source RWD to Analysis Data Introduction to Real-World Evidence (RWE) and Data Standards The integration of Real-World Evidence (RWE) into drug development and post-marketing surveillance has gained significant momentum, particularly due to its potential to complement traditional randomized controlled trials (RCTs). Regulatory bodies, including the U.S. Food and Drug Administration (FDA), emphasize the necessity of robust data standards in ensuring the integrity of analyses derived from RWE. This article serves as a comprehensive tutorial on the regulatory expectations regarding traceability from source RWD to analysis data, highlighting frameworks such as the Clinical Data Interchange Standards…

Designing Common Data Models that Support RWE Across Indications Designing Common Data Models that Support RWE Across Indications In the rapidly evolving landscape of healthcare data, designing common data models that support real-world evidence (RWE) across indications is critical for effective regulatory submissions and health outcomes research. This tutorial provides a step-by-step guide for regulatory, biostatistics, HEOR, and data standards professionals in pharma and medtech to navigate the complexities of data standards such as CDISC, SDTM, ADaM, and HL7/FHIR. Establishing a clear framework is essential for ensuring compliance and optimizing the utilization of RWE in regulatory settings. Understanding the Importance…